<DOC>
	<DOC>NCT01826214</DOC>
	<brief_summary>The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.</brief_summary>
	<brief_title>Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Subjects must have relapsed or primary refractory nonM3 acute myeloid leukemia or relapsed or refractory nonTcell acute lymphoblastic leukemia or untreated acute myeloid leukemia in elderly patients. Performance status of 0, 1 or 2 per WHO classification. Adequate renal and liver function. Adequate blood creatine kinase value (CK &lt; 1.5ULN) Allogeneic stem cell transplantation within the last 4 months and/or active graft versus host disease requiring systemic immunosuppressant therapy, or autologous stem cell transplantation within the last 4 weeks. Patient for which immediate allogeneic stem cell transplantation is the treatment of choice. Pregnant or nursing (lactating) women. Active CNS leukemic involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>leukemia</keyword>
	<keyword>acute</keyword>
	<keyword>LDE225</keyword>
	<keyword>adult patients</keyword>
	<keyword>relapsed/refractory</keyword>
</DOC>